New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices
Retrieved on:
Wednesday, October 6, 2021
Biotechnology, Diabetes, Health, Medical Devices, Abbott Laboratories, Food, Securities Act of 1933, OTCQB, Form 10-Q, MARD, Risk, Annual report, Security (finance), Private Securities Litigation Reform Act, FDA, U.S. Securities and Exchange Commission, Investor relations, 8-K, Miniaturization, Libre, SEC filing, Food and Drug Administration, Abbott, Company, Corona Labs Inc., Founder, Technology, Research, Laboratory, Securities Exchange Act of 1934, Foot, SEC, Medical device, Fine chemical
MARD is the most common metric used to assess the performance of glucose monitoring systems, with a low percentage indicating the glucose readings are close to the reference glucose value, validating the devices accuracy.
Key Points:
- MARD is the most common metric used to assess the performance of glucose monitoring systems, with a low percentage indicating the glucose readings are close to the reference glucose value, validating the devices accuracy.
- I couldnt be prouder of the work done by our team, said Phil Bosua, Know Labs CEO and Bio-RFID inventor.
- The Bio-RFID sensor is the core component of Know Labs KnowU and UBand, two non-invasive glucose monitoring devices that will address different market segments.
- Know Labs is focused on launching what the company believes will be the worlds first non-invasive medical-grade glucose monitoring solution.